Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TXBXQ
ADC Name
CN110088138A ADC-1
Synonyms
CN110088138A_ADC-1
   Click to Show/Hide
Organization
Regeneron Pharmaceuticals Inc.
Drug Status
Investigative
Drug-to-Antibody Ratio
2.7
Antibody Name
Anti-STEAP2 mAb
  Antibody Info 
Antigen Name
Metalloreductase STEAP2 (STEAP2)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
CN110088138A ADC-1 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 99.8
%
CVCL_4782
Lymph node metastasis of prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_4782
Lymph node metastasis of prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_4782
Lymph node metastasis of prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_4782
Lymph node metastasis of prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_4782
Lymph node metastasis of prostate carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_4782
Lymph node metastasis of prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.80% Positive STEAP2 expression (STEAP2+++/++)
Method Description
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 5 mg/kg ADC.

   Click to Show/Hide
In Vivo Model C4-2 CDX model
In Vitro Model Lymph node metastasis of prostate carcinoma LNCaP C4-2 cells CVCL_4782
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive STEAP2 expression (STEAP2+++/++)
Method Description
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 11.33 mg/kg ADC.

   Click to Show/Hide
In Vivo Model C4-2 CDX model
In Vitro Model Lymph node metastasis of prostate carcinoma LNCaP C4-2 cells CVCL_4782
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive STEAP2 expression (STEAP2+++/++)
Method Description
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 20 mg/kg ADC.

   Click to Show/Hide
In Vivo Model C4-2 CDX model
In Vitro Model Lymph node metastasis of prostate carcinoma LNCaP C4-2 cells CVCL_4782
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive STEAP2 expression (STEAP2+++/++)
Method Description
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 30 mg/kg ADC.

   Click to Show/Hide
In Vivo Model C4-2 CDX model
In Vitro Model Lymph node metastasis of prostate carcinoma LNCaP C4-2 cells CVCL_4782
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive STEAP2 expression (STEAP2+++/++)
Method Description
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 20 mg/kg ADC.

   Click to Show/Hide
In Vivo Model C4-2 CDX model
In Vitro Model Lymph node metastasis of prostate carcinoma LNCaP C4-2 cells CVCL_4782
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive STEAP2 expression (STEAP2+++/++)
Method Description
Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 10 mg/kg ADC.

   Click to Show/Hide
In Vivo Model C4-2 CDX model
In Vitro Model Lymph node metastasis of prostate carcinoma LNCaP C4-2 cells CVCL_4782
References
Ref 1 Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof.